Target intelligence / Profile preview

Neuraminidase (NA) (Influenza B virus) (NA)

Target
NA
Molecular classification
Enzyme, Glycoside hydrolase, Sialidase, Viral surface glycoprotein
01

Overview

Neuraminidase (NA) is a critical surface glycoprotein and enzyme found on the Influenza B virus (UniProt: P03474). Its primary biological function is to catalyze the cleavage of terminal sialic acid residues from glycoproteins and glycolipids on the surface of infected host cells and progeny virions (PubMed: PMID: 22226677). This enzymatic activity is essential for the release of newly formed viral progeny from the host cell, preventing viral aggregation and allowing the infection to spread to uninfected cells. Additionally, NA helps the virus navigate through the respiratory tract by degrading sialic acid-containing mucins in the mucus layer (NCBI: TaxID 11520). In the context of disease, Influenza B is a major cause of seasonal epidemics, and NA serves as a key virulence factor. Because of its indispensable role in the viral life cycle, NA is the primary target for the neuraminidase inhibitor (NAI) class of antiviral drugs, such as oseltamivir and zanamivir (PubChem: CID 65028). These drugs bind to the highly conserved active site of the enzyme, blocking its function and effectively trapping the virus on the cell surface. Monitoring for mutations in the NA gene is vital, as specific amino acid substitutions can lead to reduced drug susceptibility and clinical resistance.

Other names
SialidaseExo-alpha-sialidaseNeuraminidase proteinNA proteinInfluenza B virus NA
02

Mechanism of action

Neuraminidase inhibitors act as transition-state analogues that bind to the highly conserved active site of the enzyme, preventing the cleavage of terminal sialic acid residues from host cell receptors and progeny virions.

03

Biological functions

Viral releaseViral disseminationCleavage of sialic acidMucus penetrationPrevention of viral aggregationOther
04

Disease associations

InfectionInfluenza
05

Safety considerations

Development of drug-resistant mutations (e.g., H273Y or R292K)Limited therapeutic window (optimal within 48 hours of symptom onset)Potential for neuropsychiatric adverse events in pediatric populationsGastrointestinal side effects (e.g., nausea, vomiting)
06

Interacting drugs

Oseltamivir

3 more in the full profile.

07

Biomarkers

Viral RNA load (RT-PCR)Neuraminidase inhibition assay (IC50)Viral shedding durationHemagglutination inhibition titer

Beyond the preview

Go deeper on Neuraminidase (NA) (Influenza B virus) (NA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neuraminidase (NA) (Influenza B virus) (NA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call